• 13 DE
• 14 EN

• 9 Home
• 10 Contact
• 11 Sitemap

• 7 Press
  • 7.1 Press Releases
    • 7.1.1 Company
      • 7.1.1.1 2000
      • 7.1.1.2 2009
      • 7.1.1.3 2010
      • 7.1.1.4 2001
      • 7.1.1.5 2002
      • 7.1.1.6 2003
      • 7.1.1.7 2004
      • 7.1.1.8 2005
      • 7.1.1.9 2006
      • 7.1.1.10 2007
      • 7.1.1.11 2008
    • 7.1.2 Health
  • 7.2 Photos & Logos

Merz wins patent dispute with Allergan

Frankfurt am Main, 30.10.2006

The pharmaceutical company Merz has won a significant stage in a patent dispute in the United Kingdom against the American competitor Allergan Inc. in a case relating to the pharmaceutical Xeomin® as approved for Germany. The decision was issued today by the United Kingdom`s High Court of Justice and declares the patent as issued to Allergan invalid for the territory of Great Britain.

Based on Merz´s application, the High Court of Justice has invalidated the grant of a patent to Allergan Inc., Irvine, USA relating to the use of a neurotoxic component of botulinum toxin for treating pain related to muscle activities for the territory of Great Britain. This patent with the patent number EP-B1 1 366 770 was granted in 2005 by the European Patent Office for a variety of European member states, including Germany and Great Britain.

“We are pleased about this verdict” notes the CEO of the Merz Group, Prof. Dr. Bernhard Scheuble and further explains “The decision of the English court constitutes an important step for the successful marketing of our product.”

On Merz

The focus of Merz is on pharmaceuticals for treating neurological and psychiatric diseases and disorders. Merz is a leader in the area of Alzheimer research. Merz has developed Memantine, the first active ingredient worldwide for treating moderate to severe stages of Alzheimer's disease. World wide, Memantine is the second largest product in the group of Alzheimer medication. A further area of competence of Merz is clinical and aesthetic dermatology. Besides the pharmaceuticals market, Merz is active in the health sector outside of pharmacies. Based on the established trademarks tetesept® and Merz Spezial, the company is the leading provider of products for self medication, nutraceuticals and beauty and wellness for the German speaking market. A subsidiary of Merz, Senator GmbH, is a world wide leader for writing instruments used as promotional items.

World wide, the Merz Group employs 1.900 people.

Your Contact:

Merz GmbH & Co. KGaA
Ute Weinhold
Corporate Communications
Eckenheimer Landstraße 100
60318 Frankfurt
Tel: +49-69-15 03-889
Fax: +49-69-15 03-581
E-Mail: ute.weinhold@merz.de

• 0.1 A-
• 0.2 A
• 0.3 A+
• 0.4 Print

Search

Search

Search

Login for Professionals

Login for Professionals

Merz DocCheck User Password

new user

German Websites

• Alzheimer´s
• Depression
• Dystonia
• Hair Loss
• Hyal-System
• Liver Disease
• Parkinson´s